Andrew Muskovitz, MD
Hematology & Oncology · Southfield, MINPI 1558544510
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.3%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Puma Biotechnology, Inc. accounts for 70.5% of it on its own, with 52 other manufacturers making up the rest. Reporting peaked in 2019 at $30,350 and has fallen 98.8% since, to $371 in 2025. Among hematology & oncology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 336 payments — averaging $132.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Puma Biotechnology, Inc.$31K
- AbbVie$4K
- Genentech USA, Inc.$3K
- Daiichi Sankyo Inc.$974
- Novartis$904
- Amgen$759
- plus $4K from 47 others
Across 1 payment — averaging $16,600 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$17K
What the payments were for
- Consulting fees$7,56817%
- Speaking & faculty fees$26,43359%
- Travel & lodging$3,2367%
- Food & beverage$6,32814%
- Education$3351%
- Other$6822%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$44,581 in reported general payments places this provider in the 95th percentile of 282 hematology & oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 39 | $805,065 |
| PomalystPomalidomide | 38 | $734,329 |
| Lenalidomide | 40 | $642,357 |
| CabometyxCabozantinib S-Malate | 21 | $399,172 |
| XtandiEnzalutamide | 28 | $336,746 |
| ErleadaApalutamide | 20 | $291,867 |
| LynparzaOlaparib | 16 | $282,302 |
| JakafiRuxolitinib Phosphate | 16 | $268,258 |
| CalquenceAcalabrutinib Maleate | 18 | $259,520 |
| NinlaroIxazomib Citrate | 18 | $230,324 |
| PromactaEltrombopag Olamine | 25 | $218,039 |
| InlytaAxitinib | 13 | $196,772 |
| VenclextaVenetoclax | 19 | $171,888 |
| BrukinsaZanubrutinib | 11 | $165,192 |
| ImbruvicaIbrutinib | 12 | $131,387 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $39 | $805,06539 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $129 | $734,32938 claims |
| AstraZenecaLynparza, Calquence | $128 | $541,82234 claims |
| Exelixis Inc.Cabometyx | $89 | $399,17221 claims |
| Astellas Pharma US IncXtandi | $161 | $336,74628 claims |
| Johnson & JohnsonErleada, Xarelto | $198 | $316,21038 claims |
| Incyte CorporationJakafi | $78 | $268,25816 claims |
| PfizerInlyta, Eliquis | $157 | $260,03987 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $144 | $230,32418 claims |
| NovartisPromacta | $904 | $218,03925 claims |
| AbbVieVenclexta | $3,704 | $171,88819 claims |
| Beigene USA, Inc.Brukinsa | $108 | $165,19211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 282 hematology & oncology providers in Michigan.
Other hematology & oncology in Southfield
- Faisal MusaDearborn$976K
- Mohammed Al HallakDetroit$644K
- Daniel LebovicGrosse Pointe Woods$352K
- Sreenivasa ChandanaGrand Rapids$305K
- Mohammad ChistiTroy$180K
- Gordon SrkalovicLansing$167K
- Jeffrey ZonderDetroit$88K
- Madan AroraFlint$84K
- Hadeel AssadDetroit$80K
- Wasif SaifDetroit$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.